Literature DB >> 23026133

The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism.

Prakash Chinnaiyan1, Elizabeth Kensicki, Gregory Bloom, Antony Prabhu, Bhaswati Sarcar, Soumen Kahali, Steven Eschrich, Xiaotao Qu, Peter Forsyth, Robert Gillies.   

Abstract

Although considerable progress has been made toward understanding glioblastoma biology through large-scale genetic and protein expression analyses, little is known about the underlying metabolic alterations promoting their aggressive phenotype. We conducted global metabolomic profiling on patient-derived glioma specimens and identified specific metabolic programs differentiating low- and high-grade tumors, with the metabolic signature of glioblastoma reflecting accelerated anabolic metabolism. When coupled with transcriptional profiles, we identified the metabolic phenotype of the mesenchymal subtype to consist of accumulation of the glycolytic intermediate phosphoenolpyruvate and decreased pyruvate kinase activity. Unbiased hierarchical clustering of metabolomic profiles identified three subclasses, which we term energetic, anabolic, and phospholipid catabolism with prognostic relevance. These studies represent the first global metabolomic profiling of glioma, offering a previously undescribed window into their metabolic heterogeneity, and provide the requisite framework for strategies designed to target metabolism in this rapidly fatal malignancy. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026133      PMCID: PMC4638418          DOI: 10.1158/0008-5472.CAN-12-1572-T

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.

Authors:  Jason W Locasale; Alexandra R Grassian; Tamar Melman; Costas A Lyssiotis; Katherine R Mattaini; Adam J Bass; Gregory Heffron; Christian M Metallo; Taru Muranen; Hadar Sharfi; Atsuo T Sasaki; Dimitrios Anastasiou; Edouard Mullarky; Natalie I Vokes; Mika Sasaki; Rameen Beroukhim; Gregory Stephanopoulos; Azra H Ligon; Matthew Meyerson; Andrea L Richardson; Lynda Chin; Gerhard Wagner; John M Asara; Joan S Brugge; Lewis C Cantley; Matthew G Vander Heiden
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

Review 2.  Clinical applications of metabolomics in oncology: a review.

Authors:  Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

3.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries.

Authors:  Corey D Dehaven; Anne M Evans; Hongping Dai; Kay A Lawton
Journal:  J Cheminform       Date:  2010-10-18       Impact factor: 5.514

4.  Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Authors:  Taro Hitosugi; Sumin Kang; Matthew G Vander Heiden; Tae-Wook Chung; Shannon Elf; Katherine Lythgoe; Shaozhong Dong; Sagar Lonial; Xu Wang; Georgia Z Chen; Jianxin Xie; Ting-Lei Gu; Roberto D Polakiewicz; Johannes L Roesel; Titus J Boggon; Fadlo R Khuri; D Gary Gilliland; Lewis C Cantley; Jonathan Kaufman; Jing Chen
Journal:  Sci Signal       Date:  2009-11-17       Impact factor: 8.192

5.  PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect.

Authors:  Chi V Dang
Journal:  Sci Signal       Date:  2009-11-17       Impact factor: 8.192

6.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

7.  Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat.

Authors:  Soumen Kahali; Bhaswati Sarcar; Bin Fang; Eli S Williams; John M Koomen; Philip J Tofilon; Prakash Chinnaiyan
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Authors:  Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 12.779

10.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.

Authors:  Richard Possemato; Kevin M Marks; Yoav D Shaul; Michael E Pacold; Dohoon Kim; Kıvanç Birsoy; Shalini Sethumadhavan; Hin-Koon Woo; Hyun G Jang; Abhishek K Jha; Walter W Chen; Francesca G Barrett; Nicolas Stransky; Zhi-Yang Tsun; Glenn S Cowley; Jordi Barretina; Nada Y Kalaany; Peggy P Hsu; Kathleen Ottina; Albert M Chan; Bingbing Yuan; Levi A Garraway; David E Root; Mari Mino-Kenudson; Elena F Brachtel; Edward M Driggers; David M Sabatini
Journal:  Nature       Date:  2011-08-18       Impact factor: 49.962

View more
  78 in total

1.  Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.

Authors:  Andrew R Tsen; Patrick M Long; Heather E Driscoll; Matthew T Davies; Benjamin A Teasdale; Paul L Penar; William W Pendlebury; Jeffrey L Spees; Sean E Lawler; Mariano S Viapiano; Diane M Jaworski
Journal:  Int J Cancer       Date:  2013-09-30       Impact factor: 7.396

Review 2.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

3.  Metabolic Profiling of Formalin-Fixed Paraffin-Embedded Tissues Discriminates Normal Colon from Colorectal Cancer.

Authors:  Kota Arima; Mai Chan Lau; Melissa Zhao; Koichiro Haruki; Jonathan A Nowak; Marios Giannakis; Charles S Fuchs; Shuji Ogino; Keisuke Kosumi; Kosuke Mima; Mancang Gu; Juha P Väyrynen; Tyler S Twombly; Yoshifumi Baba; Kenji Fujiyoshi; Junko Kishikawa; Chunguang Guo; Hideo Baba; William G Richards; Andrew T Chan; Reiko Nishihara; Jeffrey A Meyerhardt
Journal:  Mol Cancer Res       Date:  2020-03-12       Impact factor: 5.852

4.  A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity.

Authors:  Jaroslaw Maciaczyk; Ulf D Kahlert; Katharina Koch; Rudolf Hartmann; Julia Tsiampali; Constanze Uhlmann; Ann-Christin Nickel; Xiaoling He; Marcel A Kamp; Michael Sabel; Roger A Barker; Hans-Jakob Steiger; Daniel Hänggi; Dieter Willbold
Journal:  Cell Death Discov       Date:  2020-04-16

5.  Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma.

Authors:  Antony H Prabhu; Shiva Kant; Pravin Kesarwani; Kamran Ahmed; Peter Forsyth; Ichiro Nakano; Prakash Chinnaiyan
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 6.  Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions.

Authors:  Sameer Agnihotri; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2015-07-14       Impact factor: 12.300

Review 7.  Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.

Authors:  Peter M Clark; Wilson X Mai; Timothy F Cloughesy; David A Nathanson
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

8.  Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma.

Authors:  Pravin Kesarwani; Antony Prabhu; Shiva Kant; Prakash Chinnaiyan
Journal:  Cancer Immunol Immunother       Date:  2019-05-22       Impact factor: 6.968

9.  Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients.

Authors:  Jingyuan Su; Bingyu Guo; Tingting Zhang; Kanwen Wang; Xiaoming Li; Guobiao Liang
Journal:  Tumour Biol       Date:  2015-03-18

10.  A Landscape of Metabolic Variation across Tumor Types.

Authors:  Ed Reznik; Augustin Luna; Bülent Arman Aksoy; Eric Minwei Liu; Konnor La; Irina Ostrovnaya; Chad J Creighton; A Ari Hakimi; Chris Sander
Journal:  Cell Syst       Date:  2018-01-27       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.